Maiwald was partner of the 3rd Annual Life Science Strategy Summit on IP & Exclusivity from October 8-10 in Munich

We were proud to support the third annual Life Science Strategy Summit on IP & Exclusivity as a Platinum Partner!

This industry-leading life science legal event brought together top pharma and biotech experts for three days of practical discussions on the protection of pharmaceuticals through patent and regulatory exclusivity.

This year’s highlights included:

1. An overview of recent SPC waiver decisions and their implications for exclusivity strategies concerning generic and innovative medicines.
2. Intersections between regulatory and IP law, with industry-led sessions on clinical trials, data exclusivity, a review of case law on Tecfidera, and the pharmaceutical strategy for Europe.
3. Patentability requirements in the life sciences industry, featuring panel discussions on patent quality, G2/21, enablement, and the PTAB.
4. A session discussing the impact of the UPC on life sciences strategies, led by industry experts and a panel of judges.

Additionally, two of our colleagues participated as speakers:

• Dr. Marco Stief on 8 October at 11:10 with a presentation titled “The Manufacturing Waiver: Is the System Functioning Well and What is the Latest European Case Law?”.
• Dr. Eva Ehlich on 9 October at 15:15 with a talk on “Transcontinental Update on Regulatory and IP Strategies Surrounding Clinical Trials”.